Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment

¹ Orion Pharma
² Helsinki University Central Hospital

^* To whom correspondence should be addressed. E-mail: jaakko.puttonen{at}quintiles.com.

	Abstract

Levosimendan is a vasodilator used in the treatment of acute heart failure. In the present study, the effect of hepatic impairment on the pharmacokinetics of levosimendan and its 2 metabolites, OR-1855 and OR-1896 (pharmacologically active), was investigated in 12 healthy subjects and 12 subjects with moderate hepatic impairment due to alcoholic cirrhosis of the liver but with no heart failure. In addition, the effect of acetylator status on the pharmacokinetics of levosimendan, OR-1855, and OR-1896 was evaluated. Safety and tolerability of levosimendan were also assessed. Levosimendan was given as an intravenous infusion of 0.1 µg/kg/min for 24 hours. Levosimendan showed similar C_max, AUC, and elimination half-life (t_1/2), with a mean (±SEM) t_1/2 of 0.9 ± 0.0 hours in healthy subjects and 0.8 ± 0.1 hours in hepatically impaired subjects, respectively (not significant). The t_1/2 of OR-1855 was 61 ± 5 hours in healthy subjects and 82 ± 3 hours (P < .01) in subjects with hepatic impairment. The t_1/2 of OR-1896 was 62 ± 5 hours and 91 ± 5 hours (P < .01), respectively. However, the AUCs of OR-1855 and OR-1896 were similar in healthy volunteers and hepatically impaired subjects. The effect of acetylator status was seen as higher C_max and AUC of OR-1855 in slow acetylators. Correspondingly, higher C_max and AUC of OR-1896 were observed in rapid acetylators. Levosimendan was well tolerated in both study groups. In conclusion, the pharmacokinetics of the parent drug levosimendan was unaltered in subjects with moderate hepatic impairment, whereas the elimination of the metabolites was prolonged. However, because the maximum duration of levosimendan infusion is 24 hours, dosing adjustments of levosimendan may not be required in subjects with impaired hepatic function.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. X. Kleber, T. Bollmann, M. M. Borst, A. Costard-Jackle, R. Ewert, M. Kivikko, T. Petterson, P. Pohjanjousi, S. Sonntag, and G. Wikstrom Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study J. Clin. Pharmacol., January 1, 2009; 49(1): 109 - 115. [Full Text] [PDF]